|
12 Companies |
|
15 Products |
|
15 Products |
|
23 Mechanisms of Action |
|
0 Trials |
|
74 News |
|
| «12 |
- ||||| droxidopa / Generic mfg.
Enrollment change: NOH302: Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (clinicaltrials.gov) - Apr 21, 2014
P3, N=181, Completed, Sponsor: Chelsea Therapeutics
N=118 --> 181
- ||||| droxidopa / Generic mfg.
Enrollment change: NOH301: A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa (clinicaltrials.gov) - Apr 21, 2014
P3, N=168, Completed, Sponsor: Chelsea Therapeutics
N=118 --> 181 N=118 --> 168
- | droxidopa / Generic mfg.
Trial completion: Droxidopa in Treating Patients With Neurogenic Hypotension (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=0, Completed, Sponsor: Mount Sinai School of Medicine
N=118 --> 168 Suspended --> Completed
- | Trial completion: Diagnosis and Natural History Study of Patients With Neurological Conditions (clinicaltrials.gov) - Feb 19, 2014
P=N/A, N=600, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Suspended --> Completed Recruiting --> Completed
- Novolin R (recombinant human insulin) / Novo Nordisk
New P2 trial: Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. (clinicaltrials.gov) - Feb 13, 2014
P2, N=44, Recruiting, Sponsor: University of Massachusetts, Worcester
- | Enrollment open: PROMESA: Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach (clinicaltrials.gov) - Jan 18, 2014
P3, N=86, Recruiting, Sponsor: Dr. Johannes Levin
Recruiting --> Completed Not yet recruiting --> Recruiting
- || New P3 trial: PROMESA: Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach (clinicaltrials.gov) - Dec 9, 2013
P3, N=86, Recruiting, Sponsor: Dr. Johannes Levin
- Privigen (human immune globulin intravenous 10%) / CSL Behring
Trial completion: Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins (clinicaltrials.gov) - Dec 4, 2013
P2, N=9, Completed, Sponsor: University of Massachusetts, Worcester
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||| droxidopa / Generic mfg.
Enrollment open: A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy (clinicaltrials.gov) - Nov 12, 2013
P3, N=450, Recruiting, Sponsor: Chelsea Therapeutics
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: MSA-DOUL: Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=42, Completed, Sponsor: University Hospital, Toulouse
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change, Biopsy: ColoBioParker: Analysis of the Enteric Nervous System Using Colonic Biopsies (clinicaltrials.gov) - Sep 17, 2013
P=N/A, N=34, Completed, Sponsor: Nantes University Hospital
Recruiting --> Completed N=24 --> 34
- Trial completion, Biopsy: ColoBioParker: Analysis of the Enteric Nervous System Using Colonic Biopsies (clinicaltrials.gov) - Sep 17, 2013
P=N/A, N=34, Completed, Sponsor: Nantes University Hospital
N=24 --> 34 Recruiting --> Completed
- |||||||||| droxidopa / Generic mfg.
New P3 trial: A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy (clinicaltrials.gov) - Aug 20, 2013
P3, N=450, Recruiting, Sponsor: Chelsea Therapeutics
- Biomarker, Enrollment closed: Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension (clinicaltrials.gov) - Jul 19, 2013
P=N/A, N=50, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Bystolic (nebivolol) / Menarini, AbbVie
Enrollment closed: Nebivolol in the Supine Hypertension of Autonomic Failure (clinicaltrials.gov) - Jun 19, 2013
P=N/A, N=18, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion, IO biomarker: Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease (clinicaltrials.gov) - May 28, 2013
P=N/A, N=43, Completed, Sponsor: Rush University Medical Center
Recruiting --> Active, not recruiting Recruiting --> Completed
- droxidopa / Generic mfg.
Trial termination: Augmenting Effects of L-DOPS With Carbidopa and Entacapone (clinicaltrials.gov) - May 2, 2013
P1/2, N=14, Terminated, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Suspended --> Terminated; Study terminated due to contamination droxidopa
- Biomarker, Enrollment change: Research of Biomarkers in Parkinson Disease (clinicaltrials.gov) - Sep 25, 2012
P0, N=219, Completed, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Suspended --> Terminated; Study terminated due to contamination droxidopa N=1150 --> 219
- Biomarker, Trial completion: Research of Biomarkers in Parkinson Disease (clinicaltrials.gov) - Sep 25, 2012
P0, N=219, Completed, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
N=1150 --> 219 Recruiting --> Completed
- fluoxetine / Generic mfg.
Trial completion: MSA-Fluox: Fluoxetine in Multiple System Atrophy Patients (clinicaltrials.gov) - Feb 19, 2012
P2, N=87, Completed, Sponsor: University Hospital, Toulouse
Recruiting --> Completed Recruiting --> Completed
- |||| rasagiline / Generic mfg.
Trial completion: Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) (clinicaltrials.gov) - Feb 5, 2012
P2, N=174, Completed, Sponsor: Teva Pharmaceutical Industries
Recruiting --> Completed Active, not recruiting --> Completed
- ||| rasagiline / Generic mfg.
Enrollment change: Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) (clinicaltrials.gov) - Jan 18, 2012
P2, N=174, Completed, Sponsor: Teva Pharmaceutical Industries
Active, not recruiting --> Completed N=140 --> 174
- lithium carbonate ER / Generic mfg.
Trial termination: LAMU: Lithium in Multiple System Atrophy (clinicaltrials.gov) - Dec 18, 2011
P2, N=10, Terminated, Sponsor: Federico II University
N=140 --> 174 Active, not recruiting --> Terminated; Data Monitoring Committee decision on 22nd August 2011 for safety issues
- lithium carbonate ER / Generic mfg.
Enrollment change: LAMU: Lithium in Multiple System Atrophy (clinicaltrials.gov) - Dec 18, 2011
P2, N=10, Terminated, Sponsor: Federico II University
Active, not recruiting --> Terminated; Data Monitoring Committee decision on 22nd August 2011 for safety issues N=40 --> 10
- ||||||| droxidopa / Generic mfg.
Trial completion: NOH301: A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa (clinicaltrials.gov) - Oct 13, 2011
P3, N=168, Completed, Sponsor: Chelsea Therapeutics
N=40 --> 10 Active, not recruiting --> Completed